Article Information
PubMed
Print ISSN
Online ISSN
History
- Received December 13, 2017
- Accepted February 15, 2018
- Published online April 3, 2018.
Article Versions
- Earlier version (February 20, 2018 - 10:18).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Yusuke Masuda1,
- Shinji Yamaguchi1,
- Chikako Suzuki,
- Takahide Aburatani,
- Yuki Nagano,
- Ryuki Miyauchi,
- Eiko Suzuki,
- Naotoshi Yamamura,
- Kentaro Nagatomo,
- Hidetoshi Ishihara,
- Kazuaki Okuno,
- Futoshi Nara,
- Gabriele Matschiner,
- Ryuji Hashimoto,
- Tohru Takahashi, and
- Tomohiro Nishizawa
- End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologics & Immuno-Oncology Laboratories (F.N.), Daiichi Sankyo Co., Ltd., Tokyo, Japan; and Pieris Pharmaceuticals GmbH, Freising, Germany (G.M.)
- Address correspondence to:
Tomohiro Nishizawa, End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. E-mail: nishizawa.tomohiro.yk{at}daiichisankyo.co.jp